Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe
The DOI matches its Crossref record; 36 of the 38 references it cites were found in a registry or an index.
Abstract
BACKGROUND: There is some evidence that statins may have a protective and symptomatic benefit in Alzheimer disease (AD). The LEADe study is a randomized controlled trial (RCT) evaluating the efficacy and safety of atorvastatin in patients with mild to moderate AD. METHODS: This was an international, multicenter, double-blind, randomized, parallel-group study. Subjects had mild to moderate probable AD (Mini-Mental State Examination score 13-25), were aged 50-90 years, and were taking donepezil 10 mg daily for > or 3 months prior to screening. Entry low-density lipoprotein cholesterol levels (LDL-C) were > 95 and < 195 mg/dL. Patients were randomized to atorvastatin 80 mg/day or placebo for 72 weeks followed by a double-blind, 8-week atorvastatin withdrawal phase. Coprimary endpoints were changes in cognition (Alzheimer's Disease Assessment Scale-Cognitive Subscale [ADAS-Cog]) and global function (Alzheimer's Disease Cooperative Study Clinical Global Impression of Change [ADCS-CGIC]) at 72 weeks. RESULTS: A total of 640 patients were randomized in the study. There were no significant differences in the coprimary endpoints of ADAS-cog or ADCS-CGIC or the secondary endpoints. Atorvastatin was generally well-tolerated. CONCLUSIONS: In this large-scale randomized controlled trial evaluating statin therapy as a treatment for mild to moderate Alzheimer disease, atorvastatin was not associated with significant clinical benefit over 72 weeks. This treatment was generally well-tolerated without unexpected adverse events. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that intensive lipid lowering with atorvastatin 80 mg/day in patients with mild to moderate probable Alzheimer disease (aged 50-90), taking donepezil, with low-density lipoprotein cholesterol levels between 95 and 195 mg/dL over 72 weeks does not benefit cognition (as measured by Alzheimer's Disease Assessment Scale-Cognitive Subscale) (p = 0.26) or global function (as measured by Alzheimer's Disease Cooperative Study Clinical Global Impression of Change) (p = 0.73) compared with placebo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Some observational studies have suggested a beneficial effect of aspirin on cognition,465,466 although this was not confirmed in others.467,468”
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Cook, R. J., Dickens, B. M., & Fathalla, M. F. (2003) · Reproductive Health and Human Rights · doi:10.1093/acprof:oso/9780199241323.003.0025 · Cited by 10,769
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
A nonparametric method for automatic correction of intensity nonuniformity in MRI data
Sled, J. G., Zijdenbos, A. P., & Evans, A. C. (1998) · IEEE Transactions on Medical Imaging · doi:10.1109/42.668698 · Cited by 4,731
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Self-citationA new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Research works printed but not linked: 3
- Wolozin B, Manger J, Bryant R, Cordy J, Green RC, McKee A. Re-assessing the relationship between cholesterol, statins and Alzheimer's disease. Acta Neurol Scand Suppl 2006;185:63–70.
- Austen B, Frears E, Davies H. Cholesterol upregulates production of A[beta] 1-40 and 1-42 in transfected cells. Neurobiol Aging 2000;21:254.
- Hoglund K, Wallin A, Blennow K. Effect of statins on beta-amyloid metabolism in humans: potential importance for the development of senile plaques in Alzheimer's disease. Acta Neurol Scand Suppl 2006;185:87–92.
Cited by
Items 201–300 of 443
Statin Intolerance Clinical Guide 2018
Kajinami, K., Tsukamoto, K., Koba, S., Inoue, I., Yamakawa, M., Suzuki, S., Hamano, T., Saito, H., Saito, Y., Masuda, S., et al. (2019) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.50948 · Cited by 33
Systematic review of the efficacy of statins for the treatment of Alzheimer’s disease
Mejías-Trueba, M., Pérez-Moreno, M. A., & Fernández-Arche, M. Á. (2018) · Clinical Medicine · doi:10.7861/clinmedicine.18-1-54 · Cited by 31
Cerebrovascular Disease and Statins
Beltrán, L. M., Vallejo‐Vaz, A. J., & Grijalvo, O. M. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.778740 · Cited by 36
Cognitive Enhancers (Nootropics). Part 2: Drugs Interacting with Enzymes
Froestl, W., Muhs, A., & Pfeifer, A. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121537 · Cited by 33
Lenz, R. A., Pritchett, Y. L., Berry, S. M., Llano, D. A., Han, S., Berry, D. A., Sadowsky, C. H., Abi-Saab, W. M., & Saltarelli, M. D. (2015) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000093 · Cited by 28
Does statin use cause memory decline in the elderly?
Samaras, K., Brodaty, H., & Sachdev, P. S. (2016) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2016.03.009 · Cited by 33
“Global cognition Intact Not possible, 1 of 1 – – 1 [31] of 1 5804 No difference Impaired ADAS-Cog Possible, 2 of 4 [33,34] 1020 No change 1 [26] of 4 342 No difference”
BackgroundInfluentialThe role of PI3K/AKT pathway and its therapeutic possibility in Alzheimer's disease
Yu, H.-J., & Koh, S. (2017) · Hanyang Medical Reviews · doi:10.7599/hmr.2017.37.1.18 · Cited by 35
Association Between Serum Triglycerides and Cerebral Amyloidosis in Cognitively Normal Elderly
Choi, H. J., Byun, M. S., Yi, D., Choe, Y. M., Sohn, B. K., Baek, H., Lee, J. H., Kim, H. J., Han, J., Yoon, E. J., et al. (2016) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2016.03.001 · Cited by 31
Carlsson, C. M., Xu, G., Wen, Z., Barnet, J. H., Blazel, H. M., Chappell, R. J., Stein, J. H., Asthana, S., Sager, M. A., Alsop, D. C., et al. (2012) · Current Alzheimer Research · doi:10.2174/156720512803251075 · Cited by 32
Cooper, S., Ademola, T., CASLAKE, M. J., Douglas, E. A., Evans, J. J., Greenlaw, N., Haig, C. E., Hassiotis, A., Jahoda, A. J., McConnachie, A., et al. (2016) · Trials · doi:10.1186/s13063-016-1370-9 · Cited by 30
Simvastatin inhibits protein isoprenylation in the brain
Ostrowski, S. M., Johnson, K., Siefert, M. E., Shank, S. S., Sironi, L., Wolozin, B. L., Landreth, G. E., & Ziady, A. G. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.04.053 · Cited by 30
Benefits and Harms of Statins in People with Dementia: A Systematic Review and Meta‐Analysis
Davis, K. A. S., Bishara, D., Perera, G., Molokhia, M., Rajendran, L., & Stewart, R. J. (2020) · Journal of the American Geriatrics Society · doi:10.1111/jgs.16342 · Cited by 29
Treatment of Vascular Cognitive Impairment
Ritter, A. R., & Pillai, J. A. (2015) · Current Treatment Options in Neurology · doi:10.1007/s11940-015-0367-0 · Cited by 30
Investigational medications for treatment of patients with Alzheimer disease.
Potter, P. E. (2010) · PubMed · Cited by 36
New and emerging treatments for Alzheimer's disease
Corbett, A., & Ballard, C. G. (2012) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2012.675327 · Cited by 27
Loss-of-function PCSK9 mutations are not associated with Alzheimer disease
Paquette, M., Saavedra, Y. G. L., Poirier, J., Théroux, L., Dea, D., Baass, A., & Dufour, R. (2018) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988718764330 · Cited by 26
Disease Modifying Drugs Targeting β-Amyloid
Ozudogru, S. N., & Lippa, C. F. (2012) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317512452034 · Cited by 33
“Atorvastatin 80 mg/d was not associated with significant clinical benefit over 72 weeks.(31) Cholesterol Lowering Agent to Slow Progression of AD is a phase 3 research study to investigate the safety and effectiveness of simvastatin to slow the progression of AD.”
BackgroundSex and APOE genotype differences related to statin use in the aging population
Dagliati, A., Peek, N., Brinton, R. D., & Geifman, N. (2021) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12156 · Cited by 25
Carroll, J. A., Race, B., Phillips, K. L., Striebel, J. F., & Chesebro, B. W. (2017) · Journal of General Virology · doi:10.1099/jgv.0.000876 · Cited by 26
The effect of statins on rate of cognitive decline in mild cognitive impairment
Smith, K. B., Kang, P. T., Sabbagh, M. N., & Initiative, A. D. N. (2017) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.01.001 · Cited by 26
Statin Use and Risk of Cognitive Decline in the ADNI Cohort
Kemp, E. C., Ebner, M. K., Ramanan, S., Godek, T. A., Pugh, E., Bartlett, H. H., McDonald, J. W., Mecca, M. C., van Dyck, C. H., & Mecca, A. P. (2019) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2019.11.003 · Cited by 29
“However, more conclusive multi-center trials in participants with AD-dementia have shown no effect of atorvastatin [19] or simvastatin [20] on cognitive, functional, or global outcomes in participants with AD-dementia over 18 months.”
BackgroundStatins and Cognitive Function: an Updated Review
Chatterjee, S., Krishnamoorthy, P. M., Ranjan, P., Roy, A., Chakraborty, A., Sabharwal, M. S., Ro, R., Agarwal, V., Sardar, P., Danik, J. S., et al. (2015) · Current Cardiology Reports · doi:10.1007/s11886-014-0559-3 · Cited by 24
Vevera, J., Fišar, Z., Nekovářová, T., Vrablík, M., Zlatohlávek, L., Hroudová, J., Singh, N., Raboch, J., & Valeš, K. (2016) · Physiological Research · doi:10.33549/physiolres.933264 · Cited by 24
“However, there is some controversy regarding the effect of statins on dementia: some studies have found beneficial effects, while other studies have not (Feldman et al. 2010, Padala et al. 2012, Valenti et al. 2014, Chatterjee et al. 2015).”
BackgroundRoy, S., Weinstock, J. L., Ishino, A. S., Benites, J., Pop, S. R., Perez, C., Gumbs, E. A., Rosenbaum, J. A., Roccato, M. K., Shah, H., et al. (2017) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3066w · Cited by 27
Cardiovascular manifestations of neurologic disease
Dombrowski, K. E., & Laskowitz, D. T. (2013) · Handbook of clinical neurology · doi:10.1016/b978-0-7020-4086-3.00001-1 · Cited by 24
Statins in the treatment of Alzheimer disease
Sparks, D. L. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.165 · Cited by 22
Self-citationCan the Treatment of Vascular Risk Factors Slow Cognitive Decline in Alzheimer's Disease Patients?
Richard, F., & Pasquier, F. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121012 · Cited by 25
Yanuck, D., Mihos, C. G., & Santana, O. (2012) · International Journal of Neuroscience · doi:10.3109/00207454.2012.704455 · Cited by 22
“The Liptor’s Effect in Alzheimer’s Dementia (LEADe) study [60] randomized 640 patients with mild-to-moderate AD and lowdensity lipoprotein-C levels between 95 and 195 mg/dL to 80 mg of atorvastatin or placebo daily for 72 weeks.”
BackgroundTranslating Current Knowledge Into Dementia Prevention
Román, G. C., Nash, D. T., & Fillit, H. M. (2012) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31825cbc4b · Cited by 26
Amyloid-beta metabolism in age-related neurocardiovascular diseases
Aivalioti, E., Georgiopoulos, G. A., Tual‐Chalot, S., Bampatsias, D., Delialis, D., Sopova, K., Drakos, S. G., Stellos, K., & Stamatelopoulos, K. S. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae655 · Cited by 24
“177 Some clinical benefit has been proposed by atorvastatin in mild-to-moderate AD.”
Statins for Treating Alzheimer's Disease: Truly Ineffective?
Liang, T. B., Li, R., & Cheng, O. (2015) · European Neurology · doi:10.1159/000382128 · Cited by 21
Latest advances on interventions that may prevent, delay or ameliorate dementia
Wilson, D., Peters, R., Ritchie, K. A., & Ritchie, C. W. (2011) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622310397636 · Cited by 22
“The ‘Lipitor’s Effect in AD’ (LEADe) trial included 640 participants with MMSE scores between 13 and 25 and found no effect of this statin on cognitive functioning [Feldman et al. 2010].”
BackgroundORGANIZING NUTRITION OF SCHOOLCHILDREN: PROBLEMS AND SOLUTIONS
Tapeshkina, N. V., Pochueva, L. P., & Петровна, В. О. (2019) · Fundamental and Clinical Medicine · doi:10.23946/2500-0764-2019-4-2-120-128 · Cited by 26
Statins and brain integrity in older adults: Secondary analysis of the Health ABC study
Nadkarni, N. K., Perera, S., Hanlon, J. T., López, O. L., Newman, A. B., Aizenstein, H. J., Elam, M. B., Harris, T. B., Kritchevsky, S. B., Yaffe, K. S., et al. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.11.003 · Cited by 22
Effects of lifestyle modifications on cognitive impairments in a mouse model of hypercholesterolemia
Moreira, E. L. G., Aguiar, A. S., de Carvalho, C. R., Santos, D. B., de Oliveira, J., Bem, A. F. D., Xikota, J. C., Walz, R., Farina, M., & Prediger, R. D. (2013) · Neuroscience Letters · doi:10.1016/j.neulet.2013.02.043 · Cited by 20
Combination Therapy for the Treatment of Alzheimer’s Disease: Recent Progress and Future Prospects
Shirbhate, E., Patel, V. K., Tiwari, P., Kore, R., Veerasamy, R., Mishra, A., & Rajak, H. (2022) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026622666220907114443 · Cited by 18
Hu, Z., Yuan, Y.-Q., Tong, Z., Liao, M., Yuan, S., Wu, W., Tang, Y., Wang, Y., Tang, C., & Liu, W. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612847 · Cited by 18
“Nevertheless, this contention remains subject to ongoing debate [58].”
BackgroundCooper, S., CASLAKE, M. J., Evans, J. J., Hassiotis, A., Jahoda, A. J., McConnachie, A., Morrison, J., RING, H. A., Starr, J. M., Stiles, C., et al. (2014) · Trials · doi:10.1186/1745-6215-15-202 · Cited by 18
Cognitive Function Assessment in Patients on Moderate- or High-Intensity Statin Therapy
Roy, S., Hyman, D., Ayyala, S., Bakhshi, A., Kim, S. H., Anoruo, N., Weinstock, J. L., Balogun, A., D’Souza, M., Filatova, N., et al. (2020) · Journal of Clinical Medicine Research · doi:10.14740/jocmr4144 · Cited by 18
Yasamineh, S., Mehrabani, F. J., Derafsh, E., Cosimi, R. D., Forood, A. M. K., Soltani, S., Hadi, M., & Gholizadeh, O. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03798-7 · Cited by 22
Adverse events and dropouts in Alzheimer's disease studies: What can we learn?
Henley, D. B., Sundell, K. L., Sethuraman, G., & Schneider, L. S. S. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.11.008 · Cited by 17
Schaduangrat, N., Prachayasittikul, V., Choomwattana, S., Wongchitrat, P., Phopin, K., Suwanjang, W., Malik, A. A., Vincent, B., & Nantasenamat, C. (2019) · Medicinal Research Reviews · doi:10.1002/med.21563 · Cited by 19
“Other lipid‐lowering drugs (atorvastatin and simvastatin) have been investigated as α‐secretase modulators but unfortunately, these drugs were shown to be ineffective as anti‐AD treatments.(225,226) To date, an allosteric activator of the GABAA receptor clinically used as an anxiolytic drug, namely etazolate (compound…”
BackgroundLuo, J. J., Wallace, W., & Kusiak, J. W. (2022) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2022.120294 · Cited by 17
Davidson, M. H., Szarek, M., Scheltens, P., Vijverberg, E., Hsieh, A., Ditmarsch, M., Kling, D., Curcio, D., Nicholls, S. J., Ray, K. K., et al. (2026) · The Journal of Prevention of Alzheimer's Disease · doi:10.1016/j.tjpad.2025.100394 · Cited by 16
“Prior randomized trials of statins, including simvastatin in patients with mild to moderate AD (CLASP-AD trial) and atorvastatin for prevention in mild to moderate probable AD (LEADe study), failed to demonstrate cognitive benefits [32,33].”
Dowling, N. M., Bolt, D. M., & Deng, S. (2016) · Psychological Assessment · doi:10.1037/pas0000285 · Cited by 18
“The ADAS-Cog is a rating instrument commonly used to measure cognitive dysfunction in clinical trials and for detecting, tracking, and staging AD (e.g., Aisen et al., 2008; Feldman et al., 2010; Kurz, Farlow, Quarg, & Spiegel, 2004; Rafii et al., 2011; Sano et al., 2011; Shah et al., 2013; Suzuki et al., 2013).”
MethodAlzheimer's disease clinical trials: past failures and future opportunities
Yaari, R., & Hake, A. M. (2015) · Clinical Investigation · doi:10.4155/cli.14.127 · Cited by 17
Simmons, C. R., Zou, F., Younkin, S. G., & Estus, S. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-62 · Cited by 18
Emerging amyloid and tau targeting treatments for Alzheimer’s disease
Khan, A., Corbett, A., & Ballard, C. G. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1326819 · Cited by 17
Einfluss des Lebensstils auf neurodegenerative Erkrankungen
Schulz, J. B., & Deuschl, G. (2015) · Der Nervenarzt · doi:10.1007/s00115-014-4252-y · Cited by 19
Benito‐León, J., Sánchez‐Ferro, Á., Mitchell, A. J., & Bermejo-Pareja (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s29105 · Cited by 18
Liu, H., Reynolds, G. P., & Wei, X. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-191111 · Cited by 15
An update on the diagnosis and management of dementing conditions.
Maalouf, M., Ringman, J. M., & Shi, J. (2011) · PubMed · Cited by 23
Murphy, C., Dyer, A. H., LAWLOR, B. A., Kennelly, S., & for the NILVAD study group (2023) · PLoS ONE · doi:10.1371/journal.pone.0285529 · Cited by 17
Does statin use affect amyloid beta deposition and brain metabolism?
Nabizadeh, F., Valizadeh, P., Balabandian, M., & Initiative, A. D. N. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14117 · Cited by 16
Qiu, C. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.146 · Cited by 16
Brain Lipids in the Pathophysiology and Treatment of Alzheimer’s Disease
Torres, M., Busquets, X., & Escribá, P. V. (2016) · InTech eBooks · doi:10.5772/64757 · Cited by 14
STATINS AND MEMORY LOSS: THE AUSTRALIAN PERSPECTIVE
Jamolowicz, A., Chen, H.-Y., & Panegyres, P. K. (2015) · Australasian Medical Journal · doi:10.4066/amj.2015.2014 · Cited by 16
Lee, H., & Kim, E. Y. (2020) · Archives of Pharmacal Research · doi:10.1007/s12272-020-01268-5 · Cited by 15
Dietary modulators of statin efficacy in cardiovascular disease and cognition
Wang, H., Blumberg, J. B., Chen, C. ‐. O., Choi, S., Corcoran, M. P., Harris, S. S., Jacques, P. F., Kristo, A. S., Lai, C., Lamon‐Fava, S., et al. (2014) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2014.04.001 · Cited by 16
Amyloid cascade hypothesis, tau synthesis, and role of oxidative stress in AD
Vyas, J., Raytthatha, N., & Prajapati, B. G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13205-6.00023-6 · Cited by 13
Henley, D. B., Sundell, K. L., Sethuraman, G., & Siemers, E. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.05.2413 · Cited by 14
Contu, L., Carare, R. O., & Hawkes, C. A. (2019) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12556 · Cited by 13
Dutta, S., Rahman, S., Ahmad, R., Kumar, T., Dutta, G., Banerjee, S., Abubakar, A. R., Rowaiye, A. B., Dhingra, S., Ravichandiran, V., et al. (2021) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2021.2003705 · Cited by 12
Leduc, V., Théroux, L., Dea, D., Dufour, R., & Poirier, J. (2015) · Journal of Molecular Neuroscience · doi:10.1007/s12031-015-0666-7 · Cited by 13
Mancini, G., Martins, W. C., de Oliveira, J., Bem, A. F. D., & Tasca, C. I. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02026-w · Cited by 13
Bartolomé, F. B., Muñoz, Ú., Esteras, N., Alquézar, C., Collado‐Alsina, A., Bermejo‐Pareja, F., & Martín‐Requero, Á. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0443-2 · Cited by 14
“On the other hand, while some studies examining the role of statins in established AD had shown a potential benefit in cognitive decline [14], a recent large-scale randomized controlled trial evaluating statin therapy for mild to moderate Alzheimer’s (the LEADe study) did not find significant benefit on cognition or g…”
ResultThe Effects of Statins on Prevention of Stroke and Dementia: A REVIEW
Menezes, A. R., Lavie, C. J., Milani, R. V., & O’Keefe, J. H. (2012) · Journal of Cardiopulmonary Rehabilitation and Prevention · doi:10.1097/hcr.0b013e31825d2a03 · Cited by 14
Борзалиевна, П. Т., & Барбараш, О. Л. (2019) · Fundamental and Clinical Medicine · doi:10.23946/2500-0764-2019-4-2-84-94 · Cited by 12
Sato, N., Shinohara, M., Rakugi, H., & Morishita, R. (2012) · Neurodegenerative Diseases · doi:10.1159/000334534 · Cited by 12
Drug Treatments in Development for Alzheimer's Disease
Woodward, M. C. (2012) · Journal of Pharmacy Practice and Research · doi:10.1002/j.2055-2335.2012.tb00133.x · Cited by 15
Yanai, H., Adachi, H., Hakoshima, M., & Katsuyama, H. (2024) · Molecules · doi:10.3390/molecules29245936 · Cited by 11
Kachouei, A. A., Singar, S., Wood, A., Flatt, J. D., Rosenkranz, S. K., Rosenkranz, R. R., & Akhavan, N. S. (2025) · Nutrients · doi:10.3390/nu17142328 · Cited by 14
Walker, V. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157328 · Cited by 12
Lehrer, S. P., & Rheinstein, P. H. (2018) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-170033 · Cited by 11
“to moderate Alzheimer disease, atorvastatin was not 112 associated with significant clinical benefit over 72 113 weeks [15].”
BackgroundAzizan, Z., Zali, H., Mirmotalebisohi, S. A., Bazrgar, M., & Ahmadiani, A. (2024) · PLoS ONE · doi:10.1371/journal.pone.0304410 · Cited by 11
Statins to treat Alzheimer’s disease: an incomplete story
Sabbagh, M. N., & Sparks, D. L. (2012) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.171 · Cited by 11
Self-citationImpact on Cognitive Function—Are All Statins the Same?
Shah, N. P., Swiger, K. J., & Martin, S. S. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-014-0466-5 · Cited by 11
Past and Future of Drug Treatments for Alzheimer's Disease
Kim, S. Y. (2018) · 신경정신의학 · doi:10.4306/jknpa.2018.57.1.30 · Cited by 13
Does taking statins affect the pathological burden in autopsy-confirmed Alzheimer’s dementia?
Crum, J. R., Wilson, J. R., & Sabbagh, M. N. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0430-7 · Cited by 11
Statins: the Panacea of Cirrhosis?
Cabrera, L., & Abraldeṣ, J. G. (2016) · Current Hepatology Reports · doi:10.1007/s11901-016-0287-9 · Cited by 12
Pharmacological treatment for Alzheimer's disease: current approaches and future strategies.
Fan, L., & Chiu, M. (2010) · PubMed · Cited by 30
Prevention Studies in Alzheimer’s Disease: Progress Towards the Development of New Therapeutics
Coley, N., Gallini, A., & Andrieu, S. (2015) · CNS Drugs · doi:10.1007/s40263-015-0256-9 · Cited by 12
García-Zamora, M., García‐Lluch, G., Moreno, L., Pardo, J., & Cháfer‐Pericás, C. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107446 · Cited by 11
Novel disease-modifying therapeutics for the treatment of Alzheimer’s disease
Léger, G. C., & Massoud, F. (2013) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2013.811237 · Cited by 11
Statins and therapy of Alzheimer's disease: questions of efficacy versus trial design
Wolozin, B. L. (2011) · Alzheimer s Research & Therapy · doi:10.1186/alzrt101 · Cited by 10
Chen, Y., Sun, X., Xi, Y., Luo, Z., Lai, H., Zhu, D., Zhang, Y., Xu, F., Li, J., Zhou, J., et al. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.10.016 · Cited by 10
“For instance, statin drugs have been reported to upregulate LRP1 at BBB and liver but have not proven effective in clinical trials 166 .”
Shah, U., Shah, A., Patel, S. P., Patel, A., Patel, M. M., Solanki, N. D., Patel, S., Patel, A. D., Patel, V., & Patel, B. (2022) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527322666221005124808 · Cited by 15
Medications and cognitive decline in Alzheimer's disease: Cohort cluster analysis of 15,428 patients
Jurado, P. G., Mostafaei, S., Xu, H., Mo, M., Petek, B., Kalar, I., Naia, L., Kele, J., Maioli, S., Pereira, J. B., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877241307870 · Cited by 9
Statin-Associated Adverse Events
Yuet, W. C., Khine, H., & Ahmad, Z. (2015) · Clinical Medicine Insights Therapeutics · doi:10.4137/cmt.s18865 · Cited by 10
Patient-derived iPSCs, a reliable in vitro model for the investigation of Alzheimer’s disease
Asiamah, E. A., Guo, R., Kong, D., Feng, B., He, J., Zhang, W., Liu, X., Du, X., Ma, Z., Liu, B., et al. (2021) · Reviews in the Neurosciences · doi:10.1515/revneuro-2020-0065 · Cited by 10
Video Rating in Neurodegenerative Disease Clinical Trials: The Experience of PRION-1
Carswell, C. J., Rañopa, M., Pal, S., Macfarlane, R., Siddique, D., Thomas, D. J., Webb, T., Wroe, S. J., Walker, A. S., Darbyshire, J. H., et al. (2012) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000339730 · Cited by 10
Rahman, S. O., Hussain, S., Alzahrani, A., Akhtar, M., & Najmi, A. K. (2020) · Brain Research · doi:10.1016/j.brainres.2020.147115 · Cited by 9
Shaw, C. A. (2017) · Wiley eBooks · doi:10.1002/9781118634523.refs · Cited by 10
Zimmerman, S. C., Choi, M., Jiang, C., Ferguson, E. L., Hoffmann, T. J., Swinnerton, K. N., Oni‐Orisan, A., Gilsanz, P., Meyers, T. J., Choudhary, V., et al. (2025) · Neurology · doi:10.1212/wnl.0000000000213855 · Cited by 10
Caveolae, CD109, and endothelial cells as targets for treating Alzheimer's disease
Fessel, J. (2020) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12066 · Cited by 10
Investigational drugs for the treatment of AD: what can we learn from negative trials?
Jacobson, S. A., & Sabbagh, M. N. (2011) · Alzheimer s Research & Therapy · doi:10.1186/alzrt73 · Cited by 10
Wang, J., Cheng, X., Zhang, X., Liu, G., Wang, Y., Zhou, W., & Zhang, Y. (2019) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2019.03.003 · Cited by 8
Apolipoprotein E ε-4 as a genetic determinant of Alzheimer’s disease heterogeneity
Kotze, M. J., Brand, T., Pretorius, J., van Rensburg, S. J., & Luckhoff, H. K. (2015) · Degenerative Neurological and Neuromuscular Disease · doi:10.2147/dnnd.s41721 · Cited by 15
Treatment of Alzheimer's disease in Brazil: I. Cognitive disorders
do Vale, F. D. A. C., Neto, Y. C., Bertolucci, P. H. F., Machado, J. C. B., da Silva, D. J., Allam, N., & Balthazar, M. L. F. (2011) · Dementia & Neuropsychologia · doi:10.1590/s1980-57642011dn05030005 · Cited by 10
Shang, Y., Torrandell‐Haro, G., Vitali, F., Brinton, R. D., & (ADNI), T. A. D. N. I. (2025) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70074 · Cited by 9
Metadata
- Authors
- Feldman, H. H., Doody, R. S., Kivipelto, M., Sparks, D. L., Waters, D. D., Jones, R. W., Schwam, E., Schindler, R., Hey-Hadavi, J., DeMicco, D. A., & Breazna, A.
- Affiliations
- San Francisco General Hospital (US)
- From the Division of Neurology (H.H.F.), University of British Columbia, UBCH Clinic for Alzheimer's Disease and Related Disorders, Vancouver, Canada; Department of Neurology (R.S.D.), Baylor College of Medicine, Houston, TX; Aging Research Center (M.K.), Karolinska Institutet, Stockholm, Sweden; Ralph & Muriel Roberts Laboratory For Neurodegenerative Research (D.L.S.), Sun Health Research Institute, Sun City, AZ; San Francisco General Hospital (D.D.W.), San Francisco, CA; RICE (The Research...
- Venue
- Neurology
- Published
- 2010-03-23
- Volume
- 74
- Issue
- 12
- Pages
- 956-964
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2030025114
- Cited by
- 438
- References
- 38
- Citations by year
- 2026: 9 · 2025: 21 · 2024: 14 · 2023: 12 · 2022: 10 · 2021: 18 · 2020: 27 · 2019: 42 · 2018: 16 · 2017: 26 · 2016: 34 · 2015: 26 · 2014: 33 · 2013: 28 · 2012: 49
- FWCI
- 32.49
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neurology (publishedVersion)
- PubMed (publishedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- Funders
- Pfizer
- IXICO
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- atorvastatin, Alzheimer's disease, statins, lipid lowering, donepezil, cognitive function, global function, LDL cholesterol, drug safety and efficacy
- MeSH terms
- Atorvastatin, Aged, Aged, 80 and over, Alzheimer Disease, Double-Blind Method, Female, Heptanoic Acids, Hippocampus, Humans, Cholesterol, LDL, Magnetic Resonance Imaging, Male, Middle Aged, Organ Size, Pyrroles, Cholinergic Antagonists, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.